Ilene Newman, MD
Obstetrics/Gynecology · San Jose
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- 14
- 2 carriers
- Office
- 1
On the public record
- California licence: Probation Completed
- 2 Medical Board actions on record
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Newman’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence G54610 · Current
Licensed to practise in California · since 1985 · expires 2026-10-31 · New York Medical College, New York. Board flags: Probation Completed, Admin Action By Other State/Fed Gov'T, Malpractice Judgment.
Public record actions
| 2008-02-21 | Board disciplineDiscipline | Probation completed. · 03 2003144232 |
| 2006-08-01 | Action in another state or by a federal agencyDiscipline | New york board placed dr. newman on two years probation based on action taken by the medical board of california. · Ny state board for professional med conduct |
| 2003-06-17 | Malpractice judgment | $2,169,000 · Santa clara co. superior court · CV792528 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$16,132
Medicare paid this office $16,132 for 107 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 30 | $4,836 | $161 |
| Return visit (30+ min) | 18 | $2,805 | $122 |
| New patient visit (30+ min) | 17 | $1,754 | $103 |
| Short return visit (20+ min) | 17 | $1,647 | $82 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 30 | $1,468 | $49 |
Who their Medicare patients are
107 Original Medicare patients in 2024. Average age 72 · Women 100% · Also on Medicaid 13% · Health risk score 0.88. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 70% · Diabetes 35% · Chronic kidney disease 23% · Depression 19% · Coronary heart disease 17% · Cancer 10% · Atrial fibrillation 10%.
The office billed $61,253, Medicare allowed $18,931 and paid $16,132; for 160 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 107 | 160 | 72 | 0.88 | $61,253 | $16,132 |
| 2023 | 104 | 172 | 72 | 1.25 | $52,268 | $12,994 |
| 2022 | 96 | 183 | 73 | 0.97 | $68,280 | $16,351 |
| 2021 | 93 | 149 | 74 | 1.13 | $50,954 | $12,688 |
| 2020 | 83 | 138 | 72 | 0.95 | $42,076 | $10,426 |
| 2019 | 88 | 160 | 72 | 1.01 | $53,518 | $13,328 |
| 2018 | 86 | 141 | 70 | 0.98 | $64,721 | $11,399 |
| 2017 | 114 | 213 | 71 | 0.91 | $52,894 | $14,004 |
| 2016 | 88 | 313 | 70 | 1.14 | $47,200 | $11,927 |
| 2015 | 74 | 122 | 70 | 1.12 | $43,350 | $11,683 |
| 2014 | 105 | 189 | 69 | 0.87 | $43,238 | $11,984 |
| 2013 | 95 | 190 | 72 | 1.04 | $40,127 | $18,054 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 21 | $3,385 | $113 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 52 | $2,536 | $49 |
| New patient visit (30+ min) | 14 | $1,310 | $94 |
| Short return visit (20+ min) | 14 | $1,111 | $79 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $627 | $57 |
| Short return visit | 12 | $623 | $52 |
2022: 5 services
| Return visit (30+ min) | 34 | $4,832 | $115 |
| New patient visit (30+ min) | 22 | $2,112 | $96 |
| Short return visit (20+ min) | 23 | $1,968 | $82 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 38 | $1,848 | $49 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 23 | $1,291 | $56 |
2021: 3 services
| Return visit (30+ min) | 32 | $5,636 | $120 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 41 | $2,009 | $49 |
| New patient visit (30+ min) | 16 | $1,620 | $101 |
2020: 3 services
| Return visit (30+ min) | 29 | $3,374 | $99 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 34 | $1,643 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $1,042 | $55 |
2019: 4 services
| Return visit (30+ min) | 52 | $6,297 | $87 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 26 | $1,420 | $55 |
| New patient visit (30+ min) | 11 | $1,137 | $103 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 18 | $850 | $47 |
2018: 5 services
| Return visit (30+ min) | 42 | $4,646 | $77 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,788 | $138 |
| New patient visit (30+ min) | 14 | $1,218 | $87 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 17 | $921 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 11 | $491 | $45 |
2017: 4 services
| Return visit (30+ min) | 41 | $5,464 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 52 | $2,247 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 33 | $1,725 | $52 |
| New patient visit (30+ min) | 20 | $1,674 | $84 |
2016: 5 services
| Return visit (30+ min) | 42 | $5,134 | $79 |
| New patient visit (30+ min) | 17 | $1,455 | $86 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,262 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 17 | $904 | $53 |
| Short return visit (20+ min) | 11 | $692 | $53 |
2015: 3 services
| Return visit (30+ min) | 30 | $3,505 | $83 |
| New patient visit (30+ min) | 19 | $1,970 | $104 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $999 | $48 |
2014: 3 services
| Short return visit (20+ min) | 68 | $3,963 | $57 |
| Return visit (30+ min) | 32 | $3,252 | $81 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 58 | $2,605 | $45 |
2013: 4 services
| Return visit (30+ min) | 54 | $8,150 | $90 |
| New patient visit (45+ min) | 23 | $3,311 | $144 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,312 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 16 | $885 | $55 |
Drugs they prescribed that Part D paid
$59,689
Pharmacies billed $59,689 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 344) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
246 generic and 98 brand-name prescriptions · $59,689 in drug cost · 12 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 41 | $36,715 | $895 |
| Estradiol (Once Weekly) | 53 | $6,236 | $118 |
| Estradiol | 35 | $1,879 | $54 |
| Progesterone | 28 | $1,533 | $55 |
| Alendronate | 39 | $761 | $20 |
See all 9 drugs
| Gemtesa | 41 | $36,715 | $895 |
| Estradiol (Once Weekly) | 53 | $6,236 | $118 |
| Estradiol | 35 | $1,879 | $54 |
| Progesterone | 28 | $1,533 | $55 |
| Alendronate | 39 | $761 | $20 |
| Blisovi Fe | 11 | $370 | $34 |
| Oxybutynin Chloride Er | 16 | $342 | $21 |
| Triamcinolone Acetonide | 24 | $185 | $8 |
| Paroxetine | 21 | $175 | $8 |
Year by year
| 2024 | 344 | 107 | 0% (0) | 28% | $59,689 |
| 2023 | 343 | 112 | 0% (0) | 25% | $54,221 |
| 2022 | 320 | 109 | 0% (0) | 18% | $32,867 |
| 2021 | 322 | 105 | 0% (0) | 12% | $24,517 |
| 2020 | 308 | 113 | None | 9% | $16,384 |
| 2019 | 360 | 119 | None | 9% | $26,174 |
| 2018 | 384 | 134 | 0% (0) | 16% | $41,738 |
| 2017 | 348 | 123 | None | 16% | $29,490 |
| 2016 | 256 | 94 | 0% (0) | 16% | $24,413 |
| 2015 | 218 | 93 | None | 19% | $24,233 |
| 2014 | 207 | 83 | None | None | $21,118 |
| 2013 | 280 | 105 | None | None | $24,476 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Gemtesa | 31 | $28,652 | $924 |
| Estradiol (Once Weekly) | 53 | $5,687 | $107 |
| Estradiol | 33 | $2,665 | $81 |
| Oxybutynin Chloride Er | 27 | $1,658 | $61 |
| Progesterone | 13 | $1,011 | $78 |
| Alendronate | 33 | $717 | $22 |
| Valacyclovir | 13 | $688 | $53 |
| Paroxetine | 27 | $527 | $20 |
| Acyclovir | 11 | $484 | $44 |
| Triamcinolone Acetonide | 29 | $192 | $7 |
| Medroxyprogesterone Acetate | 11 | $163 | $15 |
2022: 7 drugs
| Oxybutynin Chloride Er | 65 | $4,755 | $73 |
| Estradiol (Once Weekly) | 25 | $3,803 | $152 |
| Estradiol | 23 | $1,658 | $72 |
| Paroxetine | 22 | $457 | $21 |
| Medroxyprogesterone Acetate | 14 | $359 | $26 |
| Alendronate | 28 | $296 | $11 |
| Triamcinolone Acetonide | 36 | $270 | $8 |
2021: 7 drugs
| Premarin | 13 | $5,751 | $442 |
| Oxybutynin Chloride Er | 71 | $5,582 | $79 |
| Estradiol | 37 | $2,450 | $66 |
| Paroxetine | 20 | $510 | $25 |
| Medroxyprogesterone Acetate | 31 | $433 | $14 |
| Alendronate | 30 | $339 | $11 |
| Triamcinolone Acetonide | 35 | $311 | $9 |
2020: 6 drugs
| Oxybutynin Chloride Er | 75 | $4,703 | $63 |
| Estradiol | 24 | $1,154 | $48 |
| Paroxetine | 33 | $616 | $19 |
| Alendronate | 37 | $416 | $11 |
| Medroxyprogesterone Acetate | 20 | $357 | $18 |
| Triamcinolone Acetonide | 35 | $257 | $7 |
2019: 8 drugs
| Oxybutynin Chloride Er | 92 | $7,784 | $85 |
| Premarin | 11 | $4,205 | $382 |
| Estradiol | 31 | $1,969 | $64 |
| Oxybutynin Chloride | 17 | $1,241 | $73 |
| Paroxetine | 29 | $735 | $25 |
| Alendronate | 50 | $588 | $12 |
| Triamcinolone Acetonide | 43 | $362 | $8 |
| Medroxyprogesterone Acetate | 16 | $263 | $16 |
2018: 11 drugs
| Vesicare | 15 | $11,404 | $760 |
| Oxybutynin Chloride Er | 95 | $8,826 | $93 |
| Premarin | 18 | $5,362 | $298 |
| Estradiol | 43 | $4,041 | $94 |
| Oxybutynin Chloride | 20 | $1,530 | $76 |
| Valacyclovir | 11 | $977 | $89 |
| Paroxetine | 25 | $697 | $28 |
| Triamcinolone Acetonide | 48 | $464 | $10 |
| Medroxyprogesterone Acetate | 20 | $355 | $18 |
| Alendronate | 22 | $307 | $14 |
| Metronidazole | 13 | $105 | $8 |
2017: 11 drugs
| Vesicare | 11 | $8,088 | $735 |
| Premarin | 16 | $5,659 | $354 |
| Oxybutynin Chloride Er | 60 | $4,214 | $70 |
| Oxybutynin Chloride | 29 | $2,394 | $83 |
| Alendronate | 37 | $415 | $11 |
| Estradiol | 33 | $402 | $12 |
| Paroxetine | 17 | $363 | $21 |
| Triamcinolone Acetonide | 46 | $358 | $8 |
| Medroxyprogesterone Acetate | 16 | $244 | $15 |
| Nitrofurantoin Mono-Macro | 13 | $163 | $13 |
| Fluconazole | 17 | $91 | $5 |
2016: 7 drugs
| Vesicare | 12 | $8,505 | $709 |
| Oxybutynin Chloride | 50 | $3,988 | $80 |
| Premarin | 11 | $2,691 | $245 |
| Oxybutynin Chloride Er | 25 | $1,951 | $78 |
| Alendronate | 35 | $505 | $14 |
| Triamcinolone Acetonide | 39 | $409 | $10 |
| Metronidazole | 11 | $320 | $29 |
2015: 10 drugs
| Vesicare | 11 | $7,047 | $641 |
| Oxybutynin Chloride | 35 | $3,040 | $87 |
| Premarin | 14 | $2,698 | $193 |
| Nystatin-Triamcinolone | 14 | $2,578 | $184 |
| Oxybutynin Chloride Er | 16 | $1,569 | $98 |
| Valacyclovir | 13 | $543 | $42 |
| Alendronate | 25 | $390 | $16 |
| Metronidazole | 14 | $351 | $25 |
| Triamcinolone Acetonide | 14 | $199 | $14 |
| Estradiol | 14 | $118 | $8 |
2014: 7 drugs
| Vesicare | 12 | $6,746 | $562 |
| Oxybutynin Chloride | 31 | $2,787 | $90 |
| Oxybutynin Chloride Er | 23 | $2,360 | $103 |
| Nystatin-Triamcinolone | 11 | $1,974 | $179 |
| Premarin | 14 | $1,758 | $126 |
| Alendronate | 23 | $413 | $18 |
| Estradiol | 13 | $135 | $10 |
2013: 9 drugs
| Vesicare | 11 | $4,495 | $409 |
| Prempro | 12 | $3,265 | $272 |
| Premarin | 22 | $3,083 | $140 |
| Oxybutynin Chloride Er | 23 | $2,886 | $125 |
| Nystatin-Triamcinolone | 14 | $2,376 | $170 |
| Oxybutynin Chloride | 30 | $1,140 | $38 |
| Alendronate | 41 | $517 | $13 |
| Estradiol | 25 | $461 | $18 |
| Medroxyprogesterone Acetate | 13 | $127 | $10 |
Money from drug and device companies
$5 in 2025
| 2025 | 1 | 1 | None | $5 |
| 2024 | 1 | 9 | None | $67 |
| 2023 | 1 | 5 | None | $25 |
| 2022 | 3 | 7 | None | $84 |
| 2021 | 1 | 19 | None | $118 |
| 2020 | 1 | 1 | None | $18 |
| 2019 | 1 | 1 | None | $16 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | None | $5 | 1 payment
|
See the published payment
| Mayne Pharma Commercial | Meals · 2025-04-22 | None | $5 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $67
| Mayne Pharma Commercial | None | $67 | 9 payments
|
2023: $25
| Mayne Pharma Commercial | None | $25 | 5 payments
|
2022: $84
| Urovant Sciences | Gemtesa | $30 | 1 payment
|
| TherapeuticsMD | Annovera | $29 | 2 payments
|
| Organon | Nexplanon | $25 | 4 payments
|
2021: $118
| TherapeuticsMD | Annovera | $118 | 19 payments
|
2020: $18
| TherapeuticsMD | Annovera | $18 | 1 payment
|
2019: $16
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396856928
- Licence
- CA G54610California G54610: Current · expires 2026-10-31
- Trained
- New York Medical College, 1981
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G546100
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 227 N Jackson Ave, San Jose, CA, 95116
- NPI first listed
- 2006-08-31
- NPI last updated
- 2020-12-03
- NPI record certified
- 2020-12-03
This is when the NPI record was last certified, not a medical board exam.